Acute Respiratory Distress Syndrome Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
DelveInsight’s “Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS) , historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of the ARDS Report:
- Total incident population of ARDS in the 7MM observed to be 815,490 in 2017 for the study period 2017– 2030.
- DelveInsight’s estimates show higher incidence of ARDS in the United States with an estimated number of 497,947 cases in 2017
- Among the EU-5 countries, Germany had the highest incident population of ARDS with 148,302 cases.
- Among the EU-5 countries, Spain had the lowest incident population of 20,839 in 2017.
Key Benefits of the ARDS Report:
- Acute Respiratory Distress Syndrome Market report covers a descriptive overview and comprehensive insight of the Acute Respiratory Distress Syndrome epidemiology and Acute Respiratory Distress Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- Acute Respiratory Distress Syndrome market report provides insights on the current and emerging therapies.
- Acute Respiratory Distress Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
- Acute Respiratory Distress Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome market.
Request for Sample Page: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible.
The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.
The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.
“The highest number of incident cases were assessed for ARDS due to pneumonia, in all the 7MM countries, except the United Kingdom, in which Sepsis was the primary risk factor for ARDS”
Request for Sample Page: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
The launch of the emerging therapies is expected to significantly impact Acute Respiratory Distress Syndrome treatment scenario in the upcoming years:-
Acute Respiratory Distress Syndrome Drugs covered:
- Traumakine
- Bio-11006
- Ulinastatin
- MultiStem
- Solnatide (AP301)
- APN01 (GSK2586881)
- GSK2862277
- IC14
- Remodulin (Treprostinil Inhalation Solution)
- And Many Others
The key players in Acute Respiratory Distress Syndrome market are:
- Faron Pharmaceuticals
- BioMarck Pharmaceuticals
- Techpool Bio-Pharma
- Athersys
- APEPTICO Forschung und Entwicklung GmbH
- Apeiron Biologics/GlaxoSmithKline
- GlaxoSmithKline
- Implicit Bioscience
- United Therapeutics
- And Many Others
Request for Sample Page: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
Table of Contents:
1. Key Insights
2. Executive Summary
3. Acute Respiratory Distress Syndrome (ARDS): Market Overview at a Glance
4. Acute Respiratory Distress Syndrome (ARDS): Disease Background and Overview
5. Case Reports
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology
7. 7MM Epidemiology Analysis
8. United States Epidemiology
9. EU5 Epidemiology
9.1. Germany Epidemiology
9.2. France Epidemiology
9.3. Italy Epidemiology
9.4. Spain Epidemiology
9.5. United Kingdom Epidemiology
10. Japan Epidemiology
10.1.Assumptions and Rationale
10.2. Total Incident Population of Acute Respiratory Distress Syndrome (ARDS) in Japan
10.3. Severity-specific Incidence of ARDS in Japan
10.4. Incident Population of ARDS by Risk Factors in Japan
11. Treatment Algorithm, Current Treatment, and Medical Practices
11.1. Treatment and Support for Acute Respiratory Distress Syndrome (ARDS)
12. Proposed Guidelines for ARDS
13. Unmet Needs
14. Off-Label Therapies for ARDS
14.1.Neuromuscular Blocking Agents (NMBAs)
14.2. Inhaled Vasodilators
14.3. Corticosteroids
15. Emerging Therapies
15.1.Key Cross Competition
15.2. Traumakine: Faron Pharmaceuticals
15.3.Bio-11006: BioMarck Pharmaceuticals
15.4.Ulinastatin: Techpool Bio-Pharma
15.5.MultiStem: Athersys
15.6. Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH
List to be continued in the report……
16. Discontinued Products
16.1.APN01 (GSK2586881): Apeiron Biologics/GlaxoSmithKline
16.2.GSK2862277: GlaxoSmithKline
16.3. IC14: Implicit Bioscience
16.4.Remodulin (Treprostinil Inhalation Solution): United Therapeutics
17. Acute Respiratory Distress Syndrome (ARDS): 7MM Analysis
18. United States: Market Outlook
19. United States Market Size
20. EU-5 Countries: Market Outlook
21. Japan Market Outlook
22. Market Drivers
23. Market Barriers
24. SWOT Analysis
25. KOL Views
26. Appendix
26.1.Report Methodology
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=apr